RTW Biotech Opportunities joins $160.5m Series C of Obsidian Therapeutics
RTW Biotech Opportunities Ltd, an investment company listed on the London Stock Exchange and specialized in the life sciences sector, is proud to announce its participation in the Series C financing round of Obsidian Therapeutics, Inc. The round successfully raised $160.5 million, a testament to the high growth potential seen in Obsidian’s innovative approaches to cancer treatment. RTW Biotech, in conjunction with other investment vehicles managed by RTW Investments, LP, joined a consortium of life science-focused investment firms in this significant financial event.
Obsidian Therapeutics is at the vanguard of engineered cell and gene therapy development, aiming to revolutionize treatment for patients battling intractable diseases. With a focus on metastatic melanoma and non-small cell lung cancer, the Series C financing will notably advance clinical trials for OBX-115. This therapy represents a next-generation approach in tumor-infiltrating lymphocyte (TIL) therapy, promising to enhance patient outcomes significantly.
Lauren Lee, PhD, a Research Analyst at RTW Investments, LP, expressed enthusiasm for the funding round’s success, emphasizing the potential of OBX-115 to change the treatment landscape for melanoma and non-small cell lung cancer patients. “We are pleased to support Obsidian in this Series C financing to progress the development of OBX-115, a next-generation tumor-infiltrating lymphocyte (TIL) therapy in ongoing clinical studies that could transform outcomes for melanoma and non-small cell lung cancer patients,” stated Lee.
Obsidian’s proprietary technology leverages FDA-approved small-molecule drugs to precisely regulate protein function timing and levels, standing as a cornerstone of its therapeutic strategies. Collaborations with industry giants Bristol Myers Squibb and Vertex Pharmaceuticals further underscore Obsidian’s influential role in the biotechnology sphere.
The investment by RTW Biotech Opportunities Ltd into Obsidian’s Series C financing round not only highlights the promising future of OBX-115’s clinical development but also reaffirms the commitment of RTW and its managed investment vehicles to pioneering advancements in the life sciences sector. This strategic financial support paves the way for groundbreaking developments in engineered cell and gene therapies, potentially setting new standards in cancer treatment.
This partnership between RTW Biotech Opportunities Ltd and Obsidian Therapeutics, Inc. represents a significant milestone in the quest for innovative cancer therapies, promising hope and advanced treatment options for patients around the globe.
The successful completion of the Series C financing round for Obsidian Therapeutics, Inc., led by RTW Biotech Opportunities Ltd and other major life sciences investment firms, marks a pivotal moment in the advancement of engineered cell and gene therapies. The substantial investment underscores the potential of OBX-115 to revolutionize the treatment of metastatic melanoma and non-small cell lung cancer. As the biotechnology sector continues to evolve, such strategic investments are crucial for the development of innovative therapies that offer hope to patients facing intractable diseases.